PMID- 25581025
OWN - NLM
STAT- MEDLINE
DCOM- 20150601
LR  - 20181113
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 90
IP  - 4
DP  - 2015 Apr
TI  - Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and 
      comparison to de novo Hodgkin lymphoma.
PG  - 334-8
LID - 10.1002/ajh.23939 [doi]
AB  - Although transformation to Hodgkin lymphoma (HL) is a recognized complication in 
      patients with chronic lymphocytic leukemia (CLL), its incidence, clinical 
      characteristics and outcomes are not well defined. We used the Mayo Clinic CLL 
      and Lymphoma Databases to identify CLL patients who developed biopsy-proven HL 
      (CLL/HL) on follow-up, as well as cases of de novo HL (i.e., without prior CLL). 
      Among 3887 CLL patients seen at Mayo Clinic from January 1995 through August 
      2011, 26 (0.7%) developed HL. In a nested cohort of 2,465 newly diagnosed CLL 
      patients followed prospectively, the incidence of HL was 0.05%/year (10 year risk 
      = 0.5%). The median overall survival (OS) from date of HL diagnosis in patients 
      with CLL/HL was 3.9 years compared to not reached for de novo HL patients (n = 
      709) seen during the same time interval (P < 0.001). The shorter OS of CLL/HL 
      patients persisted after adjusting for differences in age and Ann Arbor stage of 
      disease. The International Prognostic score (IPS) developed for de novo HL 
      stratified prognosis among CLL/HL patients with median survival of not reached, 
      6.2, 2.4, and 0.3 years (P = 0.006) for those with IPS scores of </=2, 3, 4, and 
      >/=5, respectively. In summary, approximately 1 of every 200 CLL patients will 
      develop HL within 10 years. Survival after HL diagnosis in patients with CLL is 
      shorter than de novo HL patients. The IPS for de novo HL may be useful for 
      stratifying survival in CLL/HL patients.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Parikh, Sameer A
AU  - Parikh SA
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, 
      Minnesota.
FAU - Habermann, Thomas M
AU  - Habermann TM
FAU - Chaffee, Kari G
AU  - Chaffee KG
FAU - Call, Timothy G
AU  - Call TG
FAU - Ding, Wei
AU  - Ding W
FAU - Leis, Jose F
AU  - Leis JF
FAU - Macon, William R
AU  - Macon WR
FAU - Schwager, Susan M
AU  - Schwager SM
FAU - Ristow, Kay M
AU  - Ristow KM
FAU - Porrata, Luis F
AU  - Porrata LF
FAU - Kay, Neil E
AU  - Kay NE
FAU - Slager, Susan L
AU  - Slager SL
FAU - Shanafelt, Tait D
AU  - Shanafelt TD
LA  - eng
GR  - K23 CA160345/CA/NCI NIH HHS/United States
GR  - R01 CA095241/CA/NCI NIH HHS/United States
GR  - CA95241/CA/NCI NIH HHS/United States
GR  - K23CA160345/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150130
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Cell Transformation, Neoplastic/*pathology
MH  - Databases, Factual
MH  - Disease-Free Survival
MH  - Female
MH  - Hodgkin Disease/drug therapy/epidemiology/etiology/*pathology
MH  - Humans
MH  - Incidence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/complications/drug 
      therapy/epidemiology/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC4438308
MID - NIHMS688573
EDAT- 2015/01/13 06:00
MHDA- 2015/06/02 06:00
PMCR- 2016/04/01
CRDT- 2015/01/13 06:00
PHST- 2014/12/10 00:00 [received]
PHST- 2014/12/29 00:00 [revised]
PHST- 2015/01/05 00:00 [accepted]
PHST- 2015/01/13 06:00 [entrez]
PHST- 2015/01/13 06:00 [pubmed]
PHST- 2015/06/02 06:00 [medline]
PHST- 2016/04/01 00:00 [pmc-release]
AID - 10.1002/ajh.23939 [doi]
PST - ppublish
SO  - Am J Hematol. 2015 Apr;90(4):334-8. doi: 10.1002/ajh.23939. Epub 2015 Jan 30.